Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

A Dose Finding Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders

This study will test an experimental drug called ZE74-0282 in people with certain blood disorders caused by a specific mutation called JAK2 V617F. The main goals are to find the right dose level, to see how safe and tolerable different doses are, how the drug moves through the body, and whether it shows early signs of anti-tumor activity. Participants will receive ZE74-0282 in one of several dose groups. The study is open-label, meaning both the doctor and the participant know which treatment is given. It will take place at multiple centers across different countries. Blood tests and regular check-ups will be done to monitor side effects and measure the effect on the disease.

Study Overview

• Status: Not yet recruiting
• Conditions: Myelofibrosis (MF); Polycythemia Vera (PV)
• Intervention / Treatment: Drug: ZE74-0282

Detailed Description

This is a Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ZE74-0282 in patients with JAK2 V617F mutated hematologic malignancies who have received prior therapy or have declined available treatment options.

The study will be conducted in two parts:

Part 1 (Dose Escalation): Sequential cohorts of patients will receive escalating doses of ZE74-0282 to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE). Safety, tolerability, and PK will be assessed at each dose level.

Part 2 (Dose Expansion): Additional patients will be enrolled into several expansion cohorts at the MTD/RDE to further evaluate safety, tolerability, and preliminary anti-tumor activity in specific disease subtypes.

The study is expected to enroll approximately 60 patients. Adverse events will be graded according to CTCAE v6.0. Anti-tumor activity will be assessed using disease-specific response criteria.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Ekaterina Dokukina; Phone Number: +38269728309; Email: kdokukina@eilenther.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient is ≥18 years of age at the time of obtaining informed consent.
2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
3. Patient has histological confirmation JAK2 V617F mutated hematologic diagnosis with later confirmation using ipsogen® JAK2 RGQ PCR Kit) with prior therapy or who have declined them.

4. All AEs related to prior therapies (chemotherapy/systemic therapies, radiation, surgery) must have resolved to Grade 1 or baseline except for:

   1. Alopecia (Grade ≤2)
   2. Sensory neuropathy (Grade ≤2)
   3. Other AEs that have resolved to Grade ≤2 that, according to the clinical judgment of the investigator, do not constitute a safety risk to the patient.
5. Adequate hematologic function including

6. Organ function/reserve as per the following laboratory criteria:

   1. Hepatic: Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 2.5 x ULN, and total bilirubin < 2 x ULN (except for patients with known or suspected Gilbert's syndrome and with direct bilirubin within normal range) for the local laboratory. If due to disease, higher values may be approved after discussion with medical monitor.
   2. Renal: Adequate renal function as defined by calculated creatinine clearance >45 mL/min for the local laboratory.
7. Baseline corrected QT interval by Fredericia (QTcF) < 470 ms. Patients with right, left, or partial bundle branch blocks or pacemaker that may confound interpretation of this reading are not excluded from this provided they lack history of primary arrhythmic events and are cleared by cardiology for enrollment in the trial.

8. Pregnancy:

   1. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test result at screening (not applicable to patients who are unable to become pregnant, including those with bilateral oophorectomy and/or hysterectomy). The test must be performed within 72 hours before Day 1 of treatment.
   2. Women of non-child-bearing potential must have at least 12 continuous months of natural (spontaneous) amenorrhea and an appropriate clinical profile (e.g., age appropriate or history of vasomotor symptoms) or have had surgical sterilization (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) >42 days prior to screening.

9. Contraception and Gamete Donation:

   1. Male patients with a WOCBP partner must use 2 forms of acceptable contraception, including 1 barrier method, during their participation in the study and for 120 days following the last dose of the study treatment. They must also refrain from sperm donation from screening visit until 120 days following the last dose of study treatment.
   2. Women of child-bearing potential must use 2 forms of acceptable contraception, including 1 barrier method, during their participation in the study and for 120 days following the last dose of the study treatment. They must also refrain from ova donation from screening visit until 120 days following the last dose of study treatment.
10. Written informed consent must be obtained according to local guidelines and signed and dated by the patient prior to the performance of any study specific procedures, sampling, or analyses.

Exclusion Criteria:

1. Clinical signs/symptoms of leukostasis or thrombophilia require urgent therapy (phereses).
2. Known active infection with Human Immunodeficiency Virus (HIV), hepatitis B or hepatitis C. Patients with a history of positive serology for hepatitis B or C require a negative Polymerase chain reaction (PCR) test for virus to go onto therapy.
3. Disseminated intravascular coagulopathy with active, unmanageable bleeding or signs of thrombosis.
4. Patients who have received an investigational agent (for any indication) <14 days prior the first dose of ZE74-0282; an investigational agent is one for which there is no approved indication by the United States (US) FDA or by the applicable regulatory authority in the country where the study is being conducted. Additionally, the first dose of ZE74-0282 should not occur before the shorter of 28 days or a period of 5 half-lives of the investigational drug; if the half-life of the agent is unknown, patients must wait 4 weeks prior to first dose of study treatment.
5. Systemic antineoplastic or radiotherapy <14 days prior to the first day of ZE74-0282 administration (Hydroxyurea is allowed prior to study to control counts and may be given during study until completion of cycle 2.
6. Female patients who are pregnant, lactating, or planning to become pregnant or initiate breastfeeding.
7. Patients with psychological, familial, social, or geographic factors, other significant medical condition, laboratory abnormality that otherwise preclude them from giving informed consent, following the protocol, potentially hamper compliance with study treatment and follow-up or would confound the interpretation of the results of the study.
8. Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction with evidence of residual abnormalities, stroke or transient ischemic attack within 6 months prior to enrollment (Troponin (regular or high sensitivity) leak alone not included if no residual dysfunction),
9. Patients with medical comorbidities that will preclude safety evaluation of the combination should not be enrolled.
10. Patients with uncontrolled infection requiring parenteral therapy shall not be enrolled until infection is treated and brought under control (to minimum of requirement of oral antibiotics).
11. Currently participating in or has planned participation in a study of another investigational agent or device.
12. Active prior or concurrent malignancy. Such patients for whom the natural history of the malignancy or its treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational schedule are eligible for this study, if approved in writing by the sponsor. Examples of such malignancies include basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and early-stage prostate cancer undergoing watchful waiting. Patients with a completely treated prior malignancy and no evidence of disease for >2 years prior to the first dose of ZE74-0282 are eligible.
13. Patient for whom MRI OR CT imaging of spleen can not be performed on the same imaging platform throughout the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ZE74-0282 Dose Level -1; Optional and would only be performed Dose Level 1 is poorly tolerated.	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Dose Level 1	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Dose Level 2	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Dose Level 3	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Dose Level 4	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Dose Level 5	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Selected dose 1	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD
Experimental: ZE74-0282 Selected dose 2	Drug: ZE74-0282; Powder for suspension (sachets), oral, QD

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of the Recommended Phase 2 Dose	The recommended phase 2 dose (RP2D) will be defined based on the integrated review of efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) assessed in tandem across the dose expansion cohorts.	Through completion of the dose expansion phase (approximately 5 months)
Incidence of Dose-Limiting Toxicities	The incidence of dose-limiting toxicities (DLTs) assessed during Cycle 1 (from Day 1 to Day 28 of the first treatment cycle). DLTs will be graded according to CTCAE v6.0 and defined as specified in the protocol.	Cycle 1 (Day 1 through Day 28)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence, Severity, and Duration of Treatment-Emergent Adverse Events	Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE). Treatment-related TEAEs are defined as those with a reasonable possibility of being caused by the study drug.	From baseline up to Cycle 24 (28-day cycles)
Incidence of Clinically Significant Serum Chemistry Abnormalities	Number of participants with clinically significant abnormalities in chemistry parameters (Sodium, Potassium, Chloride, Bicarbonate, Total protein, Albumin, Calcium, Magnesium, Phosphorus, Glucose, BUN or urea, Creatinine, Uric acid, Total bilirubin, LDH, AST, ALT, Alkaline phosphatase, CPK, Amylase, Lipase) assessed from baseline to end of treatment (EOT).	From baseline up to Cycle 24 (28-day cycles)
Incidence of Clinically Significant Hematology Abnormalities	Number of participants with clinically significant abnormalities in hematology parameters, including but not limited to hemoglobin, white blood cell count, platelet count, and absolute neutrophil count.	From baseline up to Cycle 24 (28-day cycles)
Incidence of Clinically Significant Coagulation Abnormalities	Number of participants with clinically significant abnormalities in coagulation parameters (Activated partial thromboplastin time, Fibrinogen, International normalised ratio/ Prothrombin time).	From baseline up to Cycle 24 (28-day cycles)
Incidence of Clinically Significant Urinalysis Abnormalities	Number of participants with clinically significant abnormalities in urinalysis parameters (RBC, Glucose, Protein, Urine pH, Ketones, Bilirubin, Urine specific gravity, Blood).	From baseline up to Cycle 24 (28-day cycles)
Incidence of Clinically Significant ECG Abnormalities	Number of participants with clinically significant abnormalities on 12-lead electrocardiogram assessed from baseline to end of treatment including but not limited to the measurements of ventricular heart rate, PR interval, QRS duration, QT interval and QTcF.	From baseline up to Cycle 24 (28-day cycles).
Incidence of Grade ≥3 Adverse Events	Number of patients with adverse events of Grade 3 or higher (severe or medically significant but not immediately life-threatening; or life-threatening requiring urgent intervention; or death) assessed from baseline to end of treatment. All AEs will be graded according to the Common Terminology Criteria for Adverse Events ver. 6.0.	From baseline up to Cycle 24 (28-day cycles)
Incidence of Serious Adverse Events	Number of patients with serious adverse events, including events that result in death, are life-threatening, require hospitalization, cause significant disability, or are otherwise considered serious per ICH E6 guidelines.	From baseline up to Cycle 24 (28-day cycles)
Incidence of Treatment-Related Deaths	Number of patients with deaths considered by the investigator to be related (possibly, probably, or definitely) to the study drug. Treatment-related deaths are a subset of serious adverse events with outcome of death and a causal relationship to the investigational product.	From baseline up to Cycle 24 (28-day cycles)
Maximum Observed Plasma Concentration (Cmax) of ZE74-0282	Cmax is defined as the maximum observed plasma concentration of ZE74-0282 following study drug administration. Blood samples for PK analysis will be collected at specified time points on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 2 Day 2.	Cycle 1 (Days 1, 2, 8) and Cycle 2 (Days 1, 2).
Minimum Observed Plasma Concentration (Cmin) of ZE74-0282	Cmin is defined as the minimum observed plasma concentration of ZE74-0282 immediately prior to the next dose administration (trough concentration). Blood samples for PK analysis will be collected at specified time points on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 2 Day 2.	Cycle 1 (Days 1, 2, 8) and Cycle 2 (Days 1, 2).
Steady-State Plasma Concentration (Css) of ZE74-0282	Css is defined as the steady-state plasma concentration of ZE74-0282 achieved after repeated dosing. Blood samples for PK analysis will be collected at specified time points on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 2 Day 2.	Cycle 1 (Days 1, 2, 8) and Cycle 2 (Days 1, 2).
Area Under the Plasma Concentration-Time Curve (AUC) of ZE74-0282	AUC is defined as the area under the plasma concentration-time curve of ZE74-0282. Blood samples for PK analysis will be collected at specified time points on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 2 Day 2.	Cycle 1 (Days 1, 2, 8) and Cycle 2 (Days 1, 2).
Dose Proportionality of ZE74-0282 with Repeated Escalation	Dose proportionality will be assessed by evaluating the relationship between administered dose and systemic exposure parameters across escalating dose cohorts using a power model or analysis of variance. Blood samples for PK analysis will be collected at specified time points on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 2 Day 2.	Cycle 1 (Days 1, 2, 8) and Cycle 2 (Days 1, 2).
Partial Response or Complete Response	Number of patients who attain a best overall response of Partial Response (PR) or Complete Response (CR) as assessed by disease-specific response criteria.	From baseline up to Cycle 24 (28-day cycles).
Time to First Response and Time to Best Response	Among patients who achieve a response (Partial Response or Complete Response), the median time from start of study therapy to the first documented response (Time to First Response) and the median time from start of study therapy to the best response achieved (Time to Best Response) will be calculated. Response will be assessed using protocol-defined disease-specific criteria.	From baseline up to Cycle 24 (28-day cycles).
Duration of Response for Patients Achieving PR or CR	Among patients who achieve a response (Partial Response or Complete Response), the median duration of response will be calculated.	From baseline up to Cycle 24 (28-day cycles)
Median time from starting therapy until death	Median time from start of study therapy to death from any cause.	From baseline up to Cycle 24 (28-day cycles).
Change in JAK2 V617F Variant Allele Frequency (VAF) in Blood and Bone Marrow	Among treated patients, the median and range of maximum reduction from baseline in JAK2 V617F variant allele frequency will be assessed in peripheral blood and bone marrow samples collected during therapy.	From baseline up to Cycle 24 (28-day cycles)
Proportion of patients who eliminate V617F clone	Proportion of treated patients who achieve elimination of the JAK2 V617F mutant clone, defined as variant allele frequency (VAF) <0.02% in peripheral blood and/or bone marrow during therapy.	From baseline up to Cycle 24 (28-day cycles).
Change in Total Symptom Score	Change from baseline in Total Symptom Score (TSS) among treated patients.	From baseline up to Cycle 24 (28-day cycles).
Change in Bone Marrow Morphology Including Fibrosis	Change from baseline in bone marrow morphology, including assessment of marrow fibrosis grade.	From baseline up to Cycle 24 (28-day cycles)
Number of Patients Proceeding to Allogeneic Stem Cell Transplant	Number of patients enrolled in this study who proceed to allogeneic stem cell transplant at any time during or after study treatment.	From baseline up to Cycle 24 (28-day cycles)

Collaborators and Investigators

• Sponsor: Eilean Therapeutics

Study record dates

Study Major Dates

• Study Start (Estimated): May 15, 2026
• Primary Completion (Estimated): September 30, 2028
• Study Completion (Estimated): December 30, 2028

Study Registration Dates

• First Submitted: April 8, 2026
• First Submitted That Met QC Criteria: April 8, 2026
• First Posted (Actual): April 14, 2026

Study Record Updates

• Last Update Posted (Actual): April 14, 2026
• Last Update Submitted That Met QC Criteria: April 8, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: myelofibrosis; polycythemia vera; JAK2 V617F mutations
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Hematologic Diseases; Bone Marrow Diseases; Myeloproliferative Disorders; Bone Marrow Neoplasms; Hematologic Neoplasms; Hemic and Lymphatic Diseases; Polycythemia Vera; Primary Myelofibrosis
• Other Study ID Numbers: ZE74-0282-0002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No